Insilico Medicine Announces Positive Topline Results of ISM001-055 for the Treatment of Idiopathic Pulmonary Fibrosis (IPF) Developed Using Generative AI (IMAGE)
Caption
ISM001-055 is a potentially first-in-class small molecule targeting TNIK developed utilizing generative AI. The history of discovery, design and development including target discovery, generative chemistry, multiple in-vitro and in-vivo experiments as well as the results of Phase I clinical studies in human volunteers were published in a Nature Biotechnology article in March 2024. The medicinal chemistry portion of ISM001-055’s discovery was published in the Journal of Medicinal Chemistry in October 2024. Potential additional roles of TNIK in age-related diseases were published in Cell Trends in Pharmacological Sciences in June 2024.
Credit
Insilico Medicine
Usage Restrictions
None
License
Original content